EGFR and breast neoplasm: These changes can be reversed by treatment with DNA methyltransferase inhibitors such as azacytidine or decitabine, suggesting that patients with hypoxic breast tumors and hypomethylated EGFR status may benefit from EGFR inhibitors [57].